bibliographicCitation |
Wang X, Huang Y, Yang Z, Yang Y, Wei F, Yan M, Li F. Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer. Computational and Mathematical Methods in Medicine. 2022 Sep 17;2022():1–8. doi: 10.1155/2022/7864114. |